Baidu
map

J Natl Cancer Inst:HCV感染可增加头颈癌的发生风险

2016-07-05 MedSci MedSci原创

丙型肝炎病毒(HCV)感染与肝细胞癌和非霍奇金淋巴瘤的发生有关。2009年,MD Anderson建立了第一个用于治疗HCV感染癌症患者的诊所,在这里我们发现大量的头颈癌(HNCS)患者就诊。本研究旨在确定HCV染是否与HNCS的发生有关。采用病例对照研究,病例组为2004年到2014年就诊的感染HCV的新发原发性口咽或非口咽(口腔、鼻咽、咽、喉)HNCs病例,对照组为患有吸烟相关的(肺,食道,或

丙型肝炎病毒(HCV)感染与肝细胞癌和非霍奇金淋巴瘤的发生有关。2009年,MD Anderson建立了第一个用于治疗HCV感染癌症患者的诊所,在这里我们发现大量的头颈癌(HNCS)患者就诊。本研究旨在确定HCV感染是否与HNCS的发生有关。

采用病例对照研究,病例组为2004年到2014年就诊的感染HCV的新发原发性口咽或非口咽(口腔、鼻咽、咽、喉)HNCs病例,对照组为患有吸烟相关的(肺,食道,或膀胱)癌症。口咽癌患者进行检测活检以检测人乳头瘤病毒(HPV)。排除淋巴瘤患者。

结果共纳入了34545名HCV患者,病例组409名患者(164名口咽癌患者和245名非口咽癌患者),对照组694名(378名肺癌患者、168名食管癌患者、148名膀胱癌患者)。与对照组患者相比,口咽癌和非口咽癌患者中HCV的血清阳性率更高,尤其是HPV阳性的口咽癌患者。校正后的模型显示,HCV血清阳性率与非口咽癌(除鼻咽癌)及HPV阳性的口咽癌发生之间的关联具有统计学意义。

总而言之,HCV与非口咽癌(除鼻咽癌)和HPV阳性的口咽癌的发生相关。未来仍需进一步的研究以探讨HCV与HPV之间的相互作用,以及HCV和其他HPV相关的恶性肿瘤之间的关联。

原始出处:

Torres HA, et al. Association Between Hepatitis C Virus and Head and Neck Cancers. J Natl Cancer Inst. 2016;doi:10.1093/jnci/djw035.



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950182, encodeId=bf93195018268, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Oct 22 16:57:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881151, encodeId=3d371881151c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 05 10:57:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977516, encodeId=e8ed19e751640, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Oct 21 13:57:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257634, encodeId=5ab4125e634d3, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295873, encodeId=381b12958e3a9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618969, encodeId=5a13161896917, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92125, encodeId=0e97921258d, content=观点新颖,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 06 13:30:00 CST 2016, time=2016-07-06, status=1, ipAttribution=)]
    2016-10-22 qidongfanjian
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950182, encodeId=bf93195018268, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Oct 22 16:57:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881151, encodeId=3d371881151c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 05 10:57:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977516, encodeId=e8ed19e751640, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Oct 21 13:57:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257634, encodeId=5ab4125e634d3, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295873, encodeId=381b12958e3a9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618969, encodeId=5a13161896917, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92125, encodeId=0e97921258d, content=观点新颖,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 06 13:30:00 CST 2016, time=2016-07-06, status=1, ipAttribution=)]
    2017-04-05 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950182, encodeId=bf93195018268, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Oct 22 16:57:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881151, encodeId=3d371881151c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 05 10:57:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977516, encodeId=e8ed19e751640, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Oct 21 13:57:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257634, encodeId=5ab4125e634d3, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295873, encodeId=381b12958e3a9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618969, encodeId=5a13161896917, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92125, encodeId=0e97921258d, content=观点新颖,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 06 13:30:00 CST 2016, time=2016-07-06, status=1, ipAttribution=)]
    2016-10-21 drj2003
  4. [GetPortalCommentsPageByObjectIdResponse(id=1950182, encodeId=bf93195018268, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Oct 22 16:57:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881151, encodeId=3d371881151c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 05 10:57:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977516, encodeId=e8ed19e751640, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Oct 21 13:57:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257634, encodeId=5ab4125e634d3, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295873, encodeId=381b12958e3a9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618969, encodeId=5a13161896917, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92125, encodeId=0e97921258d, content=观点新颖,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 06 13:30:00 CST 2016, time=2016-07-06, status=1, ipAttribution=)]
    2016-07-07 ymljack
  5. [GetPortalCommentsPageByObjectIdResponse(id=1950182, encodeId=bf93195018268, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Oct 22 16:57:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881151, encodeId=3d371881151c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 05 10:57:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977516, encodeId=e8ed19e751640, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Oct 21 13:57:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257634, encodeId=5ab4125e634d3, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295873, encodeId=381b12958e3a9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618969, encodeId=5a13161896917, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92125, encodeId=0e97921258d, content=观点新颖,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 06 13:30:00 CST 2016, time=2016-07-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1950182, encodeId=bf93195018268, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Oct 22 16:57:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881151, encodeId=3d371881151c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 05 10:57:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977516, encodeId=e8ed19e751640, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Oct 21 13:57:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257634, encodeId=5ab4125e634d3, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295873, encodeId=381b12958e3a9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618969, encodeId=5a13161896917, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92125, encodeId=0e97921258d, content=观点新颖,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 06 13:30:00 CST 2016, time=2016-07-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1950182, encodeId=bf93195018268, content=<a href='/topic/show?id=f3b329482a' target=_blank style='color:#2F92EE;'>#ATL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2948, encryptionId=f3b329482a, topicName=ATL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Oct 22 16:57:00 CST 2016, time=2016-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881151, encodeId=3d371881151c2, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Apr 05 10:57:00 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977516, encodeId=e8ed19e751640, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Fri Oct 21 13:57:00 CST 2016, time=2016-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257634, encodeId=5ab4125e634d3, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295873, encodeId=381b12958e3a9, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618969, encodeId=5a13161896917, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Thu Jul 07 13:57:00 CST 2016, time=2016-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92125, encodeId=0e97921258d, content=观点新颖,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Wed Jul 06 13:30:00 CST 2016, time=2016-07-06, status=1, ipAttribution=)]
    2016-07-06 oo902

    观点新颖,值得学习

    0

相关资讯

Clin infect dis:震惊!美国CDC当前指导方针可能漏检高达四分之一的HCV感染病例

  在一项新的研究中,来自美国约翰霍普金斯医院的研究人员针对来自该医院急诊室的将近5000名患者的血液样品的评估结果提示着美国当前针对丙型肝炎病毒(HCV)的联邦指导方针可能漏检高达四分之一的HCV感染病例,因此要求更新现有的HCV筛查策略。相关研究结果将发表在2016年5月1日那期Clinical Infectious Diseases期刊上,论文标题为“Evaluation

ILC 2016:葡萄牙对所有HCV患者进行普遍治疗1年后,效果显著

2016年国际肝病会议称,在葡萄牙政府批准口服治疗所有感染丙型肝炎病毒(HCV)的患者1年后,葡萄牙HCV持续性病毒学应答率(SVR)达到96%。里斯本玛丽亚医学院肠胃肝脏专科学家Rui Tato Marinho博士说:“在真实世界,HCV的治愈率可能达到96%,不管患者伴不伴肝硬化。”葡萄牙于2015年2月17日批准口服治疗所有丙肝患者,截至2016年4月8日,Marinho报道了7011例开始

J Viral Hepat:纳尼?!HCV治疗失败也会增加肝癌风险?

根据最近公布的数据显示,干扰素治疗失败的丙型肝炎病毒感染患者相比达到持续病毒学应答的患者,其肝细胞癌风险更高。密歇根亨利福特卫生系统公共健康科学部的Mei Lu博士和同时对10,091名患者的数据进行了分析。数据显示,共有36%的患者接受了治疗,其中57%的患者治疗失败,43%的患者达到SVR。逆概率加权多因素和单因素分析处理后,治疗失败的患者与未治疗患者相比,HCC风险接近两倍(aHR = 1.

Hepatology:≥65的HCV感染者,仍可使用LDV/SOF治疗

研究者进行了一项研究,比较< 65岁 vs. ≥ 65岁人群中雷迪帕韦/索非布韦(LDV/SOF)治疗丙型肝炎(HCV)基因型1感染的安全性和有效性。 比较两组间的12周的持续病毒学应答(SVR12)、治疗相关不良事件(AEs)和实验室异常指标。研究共纳入2293名患者,其中264 (12%)名患者≥ 65岁,24名患者≥ 75岁。研究数据显示,< 65岁和≥ 65岁组SVR12分别为

Lancet Infect Dis:全球目前有超过230万艾滋和丙肝的共感染患者

近日,一项来自布里斯托大学等机构的研究人员发现,目前全球大约有230万HIV感染者同时还是丙肝感染者(HCV),相关研究刊登于The Lancet Infectious Diseases杂志上。其中有超过一半患者(130万左右)都是注射吸毒者,本文研究发现,相比未感染HIV的个体而言,感染HIV的个体发生丙肝感染的可能性是前者的6倍,这就提示卫生组织个改善HIV/HCV共感染者的相应治疗政策。

2016国际肝病会议:治疗基因型1型和4型HCV感染,Elbasvir/grazoprevir方案的安全性和疗效性更优

根据在国际肝病会议2016年发布的3期试验结果,对于基因型1型和4型的慢性丙型肝炎,每日一次,固定剂量elbasvir/grazoprevir(50mg/100mg)的片剂组合,比通常使用的治疗方案,即索非布韦(400mg)加聚乙二醇化干扰素和利巴韦林,更有效且更安全。在多中心C-EDGE头对头的研究中,研究人员随机分配255例患者接受12周elbasvir(一种NS5A抑制剂)加grazopre

Baidu
map
Baidu
map
Baidu
map